Developer of a biomarker and target discovery platform designed to help in the detection and triaging of ovarian and oth
Developer of a biomarker and target discovery platform designed to help in the detection and triaging of ovarian and other cancers.
Decision/Risk Analysis📍 South San Francisco, CAFounded 2017
Current Valuation
$601M
as of 2021-Q3
PRIVATE
QL Price
$601M
0% vs last round
QuantLogix's current estimate for InterVenn, published 2026-09-27 — in line with the last disclosed round of $601M (2021-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$601M
2021-Q3
weight 0.03
How this price has held up
No round has priced for InterVenn since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, InterVenn, 2026-09-27 (bc48669781400889).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is InterVenn going public?
No. InterVenn is private and has not filed to go public. There is no S-1 on file.
What is InterVenn's valuation in 2026?
InterVenn is valued at $601M as of 2021-Q3, set by its Series C ($201M, Aug 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has InterVenn filed an S-1?
No public S-1 is on file for InterVenn.
How much has InterVenn raised?
InterVenn has raised $244.14M in total, most recently a Series C of $201M in Aug 2021.
Is InterVenn publicly traded — can you buy InterVenn stock?
No. InterVenn is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for InterVenn on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2017
HQ
South San Francisco, CA
Employees
55
Total Raised
$244.14M
Last Round
Series C — $201M (Aug 2021)
IPO Status
private
Fundraising Status
Series C · $201M · 5y 1mo ago
privateTotal raised $244.14M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$201M
Aug 2021
—
$601M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for InterVenn — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
No public careers page or job board could be found for InterVenn as of 2026-09-16. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q3. Refreshed quarterly.